Combining esketamine with cognitive behavioral therapy for hospitalized patients with depression and suicidal thoughts
A feasibility trial of esketamine plus cognitive behavioral therapy for patients with major depressive disorder who are hospitalized for suicidal ideation
['FUNDING_R01'] · YALE UNIVERSITY · NIH-10688291
This study is looking at how well combining a fast-acting depression medication called esketamine with talk therapy can help people who are in the hospital because they are feeling suicidal, aiming to see if this mix can improve their mood and keep them safe after they leave.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | YALE UNIVERSITY (nih funded) |
| Locations | 1 site (NEW HAVEN, UNITED STATES) |
| Trial ID | NIH-10688291 on ClinicalTrials.gov |
What this research studies
This research investigates the effectiveness of combining esketamine, a rapid-acting antidepressant, with cognitive behavioral therapy (CBT) for patients hospitalized due to suicidal ideation. The study aims to assess the safety and feasibility of this combined approach to enhance the antidepressant effects of esketamine and provide ongoing support through CBT. By focusing on individuals with major depressive disorder, the research seeks to address the critical period of high risk following hospitalization. Participants will receive both treatments to evaluate their combined impact on reducing depressive symptoms and preventing suicide attempts.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are hospitalized for suicidal ideation or attempts and diagnosed with major depressive disorder.
Not a fit: Patients who are not experiencing suicidal thoughts or who do not have major depressive disorder may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment approach that significantly reduces suicidal thoughts and improves long-term mental health outcomes for patients with major depressive disorder.
How similar studies have performed: Previous research has shown promising results with esketamine and CBT separately, but this combined approach is relatively novel and has not been extensively tested.
Where this research is happening
NEW HAVEN, UNITED STATES
- YALE UNIVERSITY — NEW HAVEN, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WILKINSON, SAMUEL — YALE UNIVERSITY
- Study coordinator: WILKINSON, SAMUEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.